XSTOQLINEA
Market cap7mUSD
Dec 23, Last price
0.68SEK
1D
-11.44%
1Q
-76.19%
IPO
-98.97%
Name
Q linea AB
Chart & Performance
P/E
—
P/S
17.92
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
35.27%
Rev. gr., 5y
33.02%
Revenues
4m
-65.28%
Net income
-229m
L-16.83%
CFO
-229m
L-8.91%
Earnings
Feb 13, 2025
Profile
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 4,440 -65.28% | 12,788 36.99% | 9,335 3,741.56% | ||||||
Cost of revenue | 131,537 | 266,831 | 282,076 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (127,097) | (254,043) | (272,741) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 7,076 | 1,941 | |||||||
Tax Rate | |||||||||
NOPAT | (127,097) | (261,119) | (274,682) | ||||||
Net income | (229,366) -16.83% | (275,770) 18.26% | (233,183) 5.90% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 262,885 | 301,400 | |||||||
BB yield | -107.75% | -9.45% | |||||||
| Debt | |||||||||
Debt current | 7,659 | 6,117 | 79 | ||||||
Long-term debt | 33,469 | 29,625 | 26,470 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | (14,814) | ||||||||
Net debt | (44,862) | (39,922) | (173,305) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (228,521) | (250,863) | (255,050) | ||||||
CAPEX | (8,341) | (17,249) | (11,971) | ||||||
Cash from investing activities | (7,766) | 315,254 | (23,819) | ||||||
Cash from financing activities | 245,407 | (6,604) | 283,814 | ||||||
FCF | (157,888) | (274,159) | (309,758) | ||||||
| Balance | |||||||||
Cash | 81,895 | 72,617 | 166,034 | ||||||
Long term investments | 4,095 | 3,047 | 33,820 | ||||||
Excess cash | 85,768 | 75,025 | 199,387 | ||||||
Stockholders' equity | (1,293,728) | (1,073,342) | (804,184) | ||||||
Invested Capital | 1,503,928 | 1,241,088 | 1,232,813 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 65,941 | 29,209 | 28,239 | ||||||
Price | 3.70 -64.76% | 10.50 -90.71% | 113.00 -33.53% | ||||||
Market cap | 243,983 -20.45% | 306,699 -90.39% | 3,191,014 -25.83% | ||||||
EV | 199,121 | 266,781 | 3,018,846 | ||||||
EBITDA | (109,576) | (238,757) | (265,430) | ||||||
EV/EBITDA | |||||||||
Interest | 1,569 | 719 | 1,941 | ||||||
Interest/NOPBT | |||||||||